Capitolis Liquid Global Markets LLC Has $189.68 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Capitolis Liquid Global Markets LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 28.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 364,600 shares of the medical research company's stock after purchasing an additional 80,000 shares during the period. Thermo Fisher Scientific makes up approximately 1.8% of Capitolis Liquid Global Markets LLC's portfolio, making the stock its 14th biggest holding. Capitolis Liquid Global Markets LLC owned about 0.10% of Thermo Fisher Scientific worth $189,676,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Vanguard Group Inc. grew its stake in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock worth $17,297,426,000 after acquiring an additional 196,864 shares during the period. Capital World Investors lifted its holdings in shares of Thermo Fisher Scientific by 1.1% in the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock worth $4,905,812,000 after acquiring an additional 104,343 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock valued at $4,075,540,000 after purchasing an additional 197,442 shares during the last quarter. Norges Bank bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $3,149,754,000. Finally, Northern Trust Corp grew its stake in shares of Thermo Fisher Scientific by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after buying an additional 455,004 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on TMO shares. StockNews.com downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Finally, Citigroup decreased their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $607.43.

Insiders Place Their Bets

In related news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,075 shares of company stock worth $7,305,942. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $422.38 on Tuesday. The company's fifty day moving average price is $473.94 and its 200 day moving average price is $519.36. Thermo Fisher Scientific Inc. has a 1 year low of $409.85 and a 1 year high of $627.88. The company has a market capitalization of $159.44 billion, a PE ratio of 25.55, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same period in the prior year, the business earned $5.11 EPS. The firm's quarterly revenue was up .2% on a year-over-year basis. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.